Published in

Oxford University Press, Endocrinology, 7(144), p. 2988-2996, 2003

DOI: 10.1210/en.2003-0087

Links

Tools

Export citation

Search in Google Scholar

Cytokine-Hormone Interactions: Tumor Necrosis Factor α Impairs Biologic Activity and Downstream Activation Signals of the Insulin-Like Growth Factor I Receptor in Myoblasts

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Orange circle
Published version: archiving restricted
Data provided by SHERPA/RoMEO

Abstract

Abstract TNFα is elevated following damage to skeletal muscle. Here we provide evidence that TNFα acts on muscle cells to induce a state of IGF-I receptor resistance. We establish that TNFα inhibits IGF-I-stimulated protein synthesis in primary porcine myoblasts. Similar results were observed in C2C12 murine myoblasts, where as little as 0.01 ng/ml TNFα significantly inhibits protein synthesis induced by IGF-I. TNFα also impairs the ability of IGF-I to induce expression of a key myogenic transcription factor, myogenin. The inhibition by TNFα of IGF-I-induced protein synthesis and expression of myogenin is not due to direct killing of myoblasts by TNFα. Although IGF-I induces an approximately 19-fold induction in tyrosine phosphorylation of the β-chains of its receptor, TNFα does not inhibit this autophosphorylation. Instead, TNFα significantly reduces by approximately 50% IGF-I-stimulated tyrosine phosphorylation of two of the major downstream receptor docking molecules, insulin receptor substrate (IRS)-1 and IRS-2. These results establish that low picogram concentrations of TNFα acts on both porcine and murine myoblasts to impair tyrosine phosphorylation of both IRS-1 and IRS-2, but not the receptor itself. These data are consistent with the notion that very low physiological concentrations of TNFα interfere with both protein synthesis and muscle cell development by inducing a state of IGF-I receptor resistance.